Innovative Pioneer of Sustainable Medical Solutions

NexThera Co., Ltd. is a biotech venture company leveraging its recombinant protein-based platform technology -- including peptides -- to develop a novel therapeutic and delivery platform for wet wAMD, biobetter development, and antibody-based therapeutic for thrombocytopenia. By collaborating and forging partnerships with leading universities, research institutions, hospitals, and other key opinion leaders in the industry, NexThera is dedicated to developing novel therapies, biobetters, and platforms that contribute to human health. NexThera strives to grow as a socially responsible biotech company by contributing to a thriving local bio-ecosystem, supporting job creation, and creating an environment where young and talented scientists can fully devote themselves to cutting-edge research.

We will create a differentiated bio company to fulfill the vision and values of NexThera.

CEO Message

NexThera Co., Ltd. is a new bio venture company founded in 2020. The company's key members and researchers have cultivated differentiated technological prowess and research capabilities through accumulated research activities at their affiliated universities and national research grant.

Through these efforts, the company has developed continuous and scalable pipeline technologies. In particular, NexThera’s eye drop therapeutics and delivery platform technology for wAMD and diabetic retinopathy, as well as recombinant protein-based biobetter development platform technology, demonstrate strong growth potential and draw attention from leading domestic and foreign institutional investors.

Through the development and launch of innovative and sustainable medical solutions, NexThera strives to play a leading role in driving the local bio-ecosystem.

We will grow as a socially responsible company,

contributing to the revitalization of the local

economy, job creation, and a thriving bio-ecosystem.

NexThera, Co., Ltd.

CEO, SaeGwang Park, M.D./Ph.D.

We will grow as a socially responsible company,

contributing to the revitalization of the local

economy, job creation, and a thriving bio-ecosystem.

NexThera, Co., Ltd.

CEO, SaeGwang Park, M.D./Ph.D.

VISION

To promote human health and welfare, NexThera will continue to provide innovative and sustainable medical solutions that people can trust and use, and grow by building the best therapeutics and platforms. NexThera will establish and implement common goals and principles, and adhere to the following to achieve its vision.

Act with integrity and stick to high ethical standards.

Realize continuous development and growth.

Develop innovative therapeutics and platforms to meet future unmet needs.

Ensure industrial safety, environmental protection, and social contribution at all business sites.

Achieve high shareholder returns.

Value

NexThera's identity is based on high ethical standards and a commitment to transparency. The company executes business strategies with uncompromising ethics, never compromised under any circumstances.

Commitment to Human Health

NexThera conducts business to promote human health and welfare.

Respect for Employees

NexThera provides its employees with a safe, healthy, and pleasant working environment. The company respects the diversity of its people, encourages teamwork, and provides appropriate rewards for performance. In addition, the company supports employee growth by creating an environment where continuous learning and expression of diverse opinions are respected.

Awareness of social concerns and needs

NexThera recognizes its responsibility to promote human health and welfare in the areas in which we operate. To this end, the company operates using the right environmental, health, safety, and therapeutic management practices. NexThera is also actively involved in communication, government policy, and community outreach.

Responsibility to Shareholders

NexThera is a company that strives for corporate responsibility and generating profits for our shareholders.

History

2020

02. 17.

Company established in Inje University (Gimhae, South Gyeongsang Province, South Korea)

05. 11.

Signs MOU with DongKook Pharmaceutical for joint development of eye drop therapeutic for wet age-related macular degeneration (AMD)

06. 01.

Receives the “Startup Leap Package”, sponsored by the Ministry of SMEs and Startups (110,000,000 KRW)

08. 14.

Dr. Jee-Yeong Jeong appointed as CTO

11. 02.

Receives the “INNOPOLIS Grants for Public Technology Commercialization” sponsored by the Ministry of Science and ICT (165,000,000 KRW)

11. 23.

BNK VC joins Seed B round

12. 01.

Mr. Stephan Jeong appointed as COO

12. 17.

Becomes a certified venture company

12. 28.

Platinum Technology Investment joins Seed B round

2021

02. 01.

Opens Corporate Affiliated Research Institute, the NT R&D Center

03. 02.

Relocates Headquarters (Haeundae-gu, Busan, South Korea)

03. 11.

Opens Gimhae branch

03. 31.

Selected for TIPS Program (Accelerator Investment-Driven Tech Incubator Program for Startup)

04. 06.

Selected for 13th Technology Start-up incubation (Busan Economic Promotion Agency)

04. 13.

Selected for Frontier Venture by TECH Valley (Korea Technology Finance Corporation)

10.13.

KB Investment & BNK VC joins Series A round

10.18.

Korea Technology Finance Corporation(Kibo) joins Series A round

2022

01. 08.

DAOL Investment (ex. KTB Networks)/KB Securities, Platinum Technology Investment joined Series A round

03. 02.

HQ, R&D center Relocation (4F, Busan Office Bldg. Busan, Korea)

11. 01.

Selected as a Baby Unicorn Company by the Ministry of SMEs and Startups

2023

04. 27.

Selected for the Leading Substance Sector of the National New Drug Development Project

06. 16.

Successful Evaluation (Excellent) in the Startup and Growth Technology Development Program (TIPS)

12. 05.

Solidus Investment, WOORI Venture Partners(ex. KTB Networks/ DAOL Investment), KB Investment joined Series A-1 round

2024

03. 12

Domestic Distribution Rights Agreement and Joint Development Agreement - EyeGene, Inc / Korean BMI.

04. 01

Selected for the Startup Leap Package organized by Busan Economic Promotion Agency

05. 10

KCRN Research, lnc. joined Series A-1 round

06. 03

Selected for the Startup Leap Package organized by the Korea Institute of Startup & Entrepreneurship Development

08. 02

Selected for the Materials-Components Technology Development Program by Korea Planning & Evaluation of Industrial Technology

Ethics Management

Ethics Charter

•

NexThera is a proud contributor to human welfare by effectively addressing projects of unmet medical needs, that help grow and advance the biopharmaceutical industry.

•

We strive to be a global biotech venture that is respected and trusted by the global market through ethics and compliance practices of the highest standard.

•

We will fulfill our vision through creative thinking and adventurous mindset, and we will always conduct business based on fair and honest attitudes, striving to foster a clean environment with no corruption.

•

We will dedicate ourselves to research & development with the goal of advancing human health and the biopharmaceutical industry in mind.

•

We will achieve shared prosperity by complying with domestic and international laws and regulations, and establishing a cooperative working relationship with all stakeholders.

•

We will treat each employee with respect and fairness. We will not discriminate against any employee, ensure that we provide them with equal opportunities and evaluations, and contribute to improving their health and quality of life.

•

We will actively participate in community activities and constantly work towards value creation to contribute to the development of the country and society.

Ensure ethics and compliance in observance of laws & principles,

achieve the 4th industrial revolution through internalization,

and demonstrate strong R&D capabilities.

Establish NexThera as a high integrity company that promotes clean, transparent management

Become an example for others on honest and ethical management